Catalio Capital Management, LP
Catalio Capital Management is a multi-strategy investment firm founded in 2020 by George Petrocheilos and R. Jacob Vogelstein. The firm focuses on investing in breakthrough biomedical technology and innovative healthcare companies worldwide. Catalio aims to produce extraordinary returns by creating and sustaining life sciences companies that combine cutting-edge science and technology with top-tier management and execution. The firm collaborates with leading scientists, engineers, and clinicians to identify breakthrough biotechnologies, co-invest with top-tier funds, and recruit top talent from their networks.
Catalio Capital Management, LP
512 W. 22nd Street, 5th Floor, New York, NY 10011
What We Do
Invests in privately held breakthrough biomedical technology companies at all stages, from seed to crossover.
Provides senior-secured financing to breakthrough biomedical technology companies.
A long bias, fundamental, bottoms-up equity long/short strategy investing in global healthcare equities across sectors: innovative drugs, devices, diagnostics, and data.
Provides Catalio Limited Partners with direct access to the firm's best deals.
Geographic Focus
Portfolio
Developing T-cell therapeutics for solid tumors, leveraging advances in TCR engineering.
#Biotechnology
Uses machine learning to inform DNA-encoded library screens and expedite drug development.
#Drug Discovery
In-licensing mature, de-risked assets from Asia with first-in-class or best-in-class potential in the US/EU.
#Drug Development
Pursuing commercial applications of a novel dendrimer technology for brain and ocular disorders.
#Pharmaceuticals
Dedicated to changing the paradigm for treating mental health disorders such as depression, anxiety, and addiction.
#Mental Health